Literature DB >> 1846327

Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

N Yasuda1, P K Lai, J Rogers, D T Purtlo.   

Abstract

We studied the cellular function and lymphokine production of T cells from patients with X-linked lymphoproliferative disease (XLP) when activated by the challenge with Epstein-Barr virus (EBV) infection. We used an assay system in which T cells were stimulated with membrane antigens of autologous EBV-infected B lymphoblastoid cell lines (B-LCL) and we examined cellular and humoral factors derived from the stimulated T cells which control the growth of EBV-infected B-LCL. Immunoglobulin secretion from the autologous B-LCL was suppressed with radiosensitive suppressor cells in the patients with XLP. The degree of suppression was correlated with the immunoglobulin levels in the serum of the patients with acquired hypogammaglobulinaemia (P less than 0.05). In addition, T cells from the patients with XLP failed to produce interferon-gamma (IFN-gamma) (P less than 0.001). Moreover, the T cell supernatants from the patients with XLP were less potent to inhibit the B-LCL growth. This diminished inhibition of the B-LCL growth was correlated well with the decreased concentration of IFN-gamma in the T cell supernatants. These findings suggest that suppressor cells may be activated in the patients with the hypogammaglobulinaemia phenotype of XLP, but the frequent development of B cell lymphoma in hypogammaglobulinaemia indicate that immunoglobulin suppression may not exert enough pressure on the in vivo growth of EBV-infected B cells. The defective secretion of IFN-gamma may be, at least partially, responsible for the abnormal cytotoxic T cell and natural killer activities found in the patients with XLP, and may indicate the clinical evaluation about the preventive injection of IFN-gamma against the development of malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846327      PMCID: PMC1535448          DOI: 10.1111/j.1365-2249.1991.tb05580.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  Immunodeficiency to the Epstein-Barr virus in the X-linked recessive lymphoproliferative syndrome.

Authors:  D T Purtilo; L Hutt; J Bhawan; J P Yang; C Cassel; S Allegra; F S Rosen
Journal:  Clin Immunol Immunopathol       Date:  1978-02

3.  Study of the mechanism for in vitro activation of mouse NK cells by interferon.

Authors:  A Senik; J P Kolb; A Orn; M Gidlund
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

4.  Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome.

Authors:  S Harada; T Bechtold; J K Seeley; D T Purtilo
Journal:  Int J Cancer       Date:  1982-12-15       Impact factor: 7.396

5.  Single step separation of human T and B cells using AET treated srbc rosettes.

Authors:  A Saxon; J Feldhaus; R A Robins
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

6.  Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2.

Authors:  W L Farrar; H M Johnson; J J Farrar
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

7.  Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome.

Authors:  S Argov; D R Johnson; M Collins; H S Koren; H Lipscomb; D T Purtilo
Journal:  Cell Immunol       Date:  1986-06       Impact factor: 4.868

8.  Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

9.  Deficient natural killer cell activity in x-linked lymphoproliferative syndrome.

Authors:  J L Sullivan; K S Byron; F E Brewster; D T Purtilo
Journal:  Science       Date:  1980-10-31       Impact factor: 47.728

10.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

View more
  4 in total

Review 1.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP.

Authors:  M J Czar; E N Kersh; L A Mijares; G Lanier; J Lewis; G Yap; A Chen; A Sher; C S Duckett; R Ahmed; P L Schwartzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

3.  X-linked lymphoproliferative disease in an adult.

Authors:  Takumi Hoshino; Hirokazu Kanegane; Noriko Doki; Hiroyuki Irisawa; Tohru Sakura; Yoshihisa Nojima; Shuichi Miyawaki; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

4.  Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease--report of three cases.

Authors:  B Hügle; P Suchowerskyj; H Hellebrand; B Adler; M Borte; U Sack; U Schulte Overberg-Schmidt; N Strnad; J Otto; A Meindl; V Schuster
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.